ZNTL

Zentalis Pharmaceuticals, Inc.

Price Chart

Latest Quote

$3.66

-0.21 (-5.43%)

Current Price

Previous Close	$3.87
Open	$3.85
Day High	$3.85
Day Low	$3.42
Volume	990,021

Fetched: 2026-06-06T00:07:47

Stock Information

Shares Outstanding	71.19M
Total Debt	$34.65M
Cash Equivalents	$211.76M
Net Income	$-124.13M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$260.54M
EPS (TTM)	$-1.74
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$83.43M
Income	$-124.13M
Book/sh	$3.13
Cash/sh	$2.97
Employees	106

Financial Ratios

Quick Ratio	6.01
Current Ratio	6.19
Debt/Eq	18.97

Returns & Margins

ROA	-27.65%
ROE	-51.93%

Ownership

Insider Ownership	22.44%
Institutional Ownership	62.06%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.35
P/B	1.17

Analyst Data

Recommendation	buy
Target Price	$6.50

Technical Indicators

SMA20	$3.98
SMA50	$3.91
SMA200	$2.42
RSI	40.58
ATR	0.2933

Shares Float	48.84M
Short Float	8.66%
Short Ratio	4.03
Rel Volume	0.99

Performance History

Week	-8.50%
Month	-12.44%
Quarter	+59.48%
6 Months	+165.22%
YTD	+167.15%
Year	+144.00%
3 Years	-85.94%
5 Years	-93.45%
10 Years	-84.22%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$3.66	999,561
2026-06-04	$3.87	566,700
2026-06-03	$3.72	1,153,100
2026-06-02	$3.95	1,668,200
2026-06-01	$3.98	699,800
2026-05-29	$4.00	675,500
2026-05-28	$4.05	327,900
2026-05-27	$4.02	500,200
2026-05-26	$3.96	650,800
2026-05-22	$4.06	546,900
2026-05-21	$4.14	864,800
2026-05-20	$3.71	1,378,400
2026-05-19	$3.54	827,200
2026-05-18	$3.63	3,193,900
2026-05-15	$4.05	918,100
2026-05-14	$4.09	2,593,400
2026-05-13	$4.28	637,300
2026-05-12	$4.28	435,600
2026-05-11	$4.14	723,400
2026-05-08	$4.41	769,300
2026-05-07	$4.23	656,200
2026-05-06	$4.18	834,100

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

📰 Latest News

Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target

Insider Monkey • 2026-04-20T14:47:44Z

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone

Simply Wall St. • 2026-04-13T02:11:09Z

Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon

MarketBeat • 2026-02-16T10:09:18Z

Mitsui Sumitomo Continues to Build WR Berkley Stake

24/7 Wall St. • 2026-01-13T13:45:57Z

A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying

Simply Wall St. • 2026-01-11T22:08:33Z

Following a 13% decline over last year, recent gains may please Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) institutional owners

Simply Wall St. • 2026-01-08T12:27:58Z

We're Keeping An Eye On Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Rate

Simply Wall St. • 2025-12-03T13:01:20Z

Pleasing Signs As A Number Of Insiders Buy Zentalis Pharmaceuticals Stock

Simply Wall St. • 2025-10-06T15:39:01Z

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the company

Simply Wall St. • 2025-07-23T16:34:04Z

Here's Why We're Watching Zentalis Pharmaceuticals' (NASDAQ:ZNTL) Cash Burn Situation

Simply Wall St. • 2025-06-26T12:04:54Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$67,425,000	$0	$0
Operating Revenue	$0	$67,425,000	$0	$0
Expenses
Total Expenses	$145,012,000	$254,883,000	$253,941,000	$227,287,000
Other Income Expense	$8,394,000	$21,768,000	$-22,951,000	$5,987,000
Operating Expense	$145,012,000	$254,883,000	$253,941,000	$227,287,000
General And Administrative Expense	$37,717,000	$87,115,000	$64,351,000	$54,553,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-137,060,000	$-165,839,000	$-292,191,000	$-236,806,000
Normalized Income	$-143,691,260	$-183,035,720	$-269,285,902	$-242,781,026
Net Income From Continuing And Discontinued Operation	$-137,060,000	$-165,839,000	$-292,191,000	$-236,806,000
Total Operating Income As Reported	$-152,808,000	$-191,194,000	$-299,509,000	$-227,287,000
Net Income Common Stockholders	$-137,060,000	$-165,839,000	$-292,191,000	$-236,806,000
Net Income	$-137,060,000	$-165,839,000	$-292,191,000	$-236,806,000
Net Income Including Noncontrolling Interests	$-137,060,000	$-165,867,000	$-292,305,000	$-237,113,000
Net Income Continuous Operations	$-137,060,000	$-165,867,000	$-292,305,000	$-237,113,000
Earnings From Equity Interest Net Of Tax	$0	$0	$-16,014,000	$-16,282,000
Pretax Income	$-136,618,000	$-165,690,000	$-276,892,000	$-221,300,000
Special Income Charges	$-7,796,000	$-3,736,000	$-45,568,000	$0
Operating Income	$-145,012,000	$-187,458,000	$-253,941,000	$-227,287,000
Per Share
Diluted EPS	-	$-2.33	$-4.47	$-4.48
Basic EPS	-	$-2.33	$-4.47	$-4.48
Other
Tax Effect Of Unusual Items	$1,762,740	$4,571,280	$-45,902	$11,974
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-152,667,000	$-207,937,000	$-229,601,000	$-231,848,000
Total Unusual Items	$8,394,000	$21,768,000	$-22,951,000	$5,987,000
Total Unusual Items Excluding Goodwill	$8,394,000	$21,768,000	$-22,951,000	$5,987,000
Reconciled Depreciation	$739,000	$1,289,000	$1,389,000	$1,426,000
EBITDA (Bullshit earnings)	$-144,273,000	$-186,169,000	$-252,552,000	$-225,861,000
EBIT	$-145,012,000	$-187,458,000	$-253,941,000	$-227,287,000
Diluted NI Availto Com Stockholders	$-137,060,000	$-165,839,000	$-292,191,000	$-236,806,000
Minority Interests	$0	$28,000	$114,000	$307,000
Tax Provision	$442,000	$177,000	$-601,000	$-469,000
Impairment Of Capital Assets	$0	$3,736,000	$0	$0
Restructuring And Mergern Acquisition	$7,796,000	$0	$0	-
Gain On Sale Of Security	$16,190,000	$25,504,000	$22,617,000	$5,987,000
Research And Development	$107,295,000	$167,768,000	$189,590,000	$172,734,000
Selling General And Administration	$37,717,000	$87,115,000	$64,351,000	$54,553,000
Other Gand A	$37,717,000	$87,115,000	$64,351,000	$54,553,000
Diluted Average Shares	-	$71,080,000	$65,409,000	$52,857,000
Basic Average Shares	-	$71,080,000	$65,409,000	$52,857,000
Gain On Sale Of Business	-	-	$0	$0
Other Special Charges	-	-	$45,568,000	-

Fetched: 2026-06-02

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$216,204,000	$337,186,000	$433,548,000	$430,067,000
Total Assets	$288,967,000	$430,337,000	$551,688,000	$539,310,000
Total Non Current Assets	$35,776,000	$44,271,000	$54,970,000	$87,377,000
Other Non Current Assets	$6,735,000	$7,044,000	$9,499,000	$12,350,000
Current Assets	$253,191,000	$386,066,000	$496,718,000	$451,933,000
Other Current Assets	$7,298,000	$9,982,000	$13,799,000	$14,562,000
Receivables	$0	$5,000,000	$0	$7,041,000
Cash Cash Equivalents And Short Term Investments	$245,893,000	$371,084,000	$482,919,000	$437,371,000
Cash And Cash Equivalents	$35,995,000	$33,901,000	$28,038,000	$43,069,000
Goodwill And Other Intangible Assets	-	$0	$3,736,000	$3,736,000
Other Receivables	-	$5,000,000	-	$6,533,000
Non Current Prepaid Assets	-	-	-	$9,723,000
Restricted Cash	-	-	-	$0
Prepaid Assets	-	-	-	$14,562,000
Accrued Interest Receivable	-	-	-	$508,000
Accounts Receivable	-	-	-	-
Debt
Total Debt	$35,704,000	$39,577,000	$43,150,000	$45,166,000
Long Term Debt And Capital Lease Obligation	$35,704,000	$39,577,000	$43,150,000	$45,166,000
Current Debt And Capital Lease Obligation	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$72,763,000	$93,151,000	$114,297,000	$105,286,000
Total Non Current Liabilities Net Minority Interest	$36,204,000	$40,426,000	$44,930,000	$48,639,000
Other Non Current Liabilities	$500,000	$849,000	$1,780,000	$2,620,000
Current Liabilities	$36,559,000	$52,725,000	$69,367,000	$56,647,000
Payables And Accrued Expenses	$36,559,000	$52,725,000	$69,367,000	$56,647,000
Payables	$7,208,000	$7,438,000	$14,926,000	$11,247,000
Accounts Payable	$7,208,000	$7,438,000	$14,926,000	$11,247,000
Non Current Deferred Liabilities	-	-	$0	$853,000
Non Current Deferred Taxes Liabilities	-	-	$0	$853,000
Total Tax Payable	-	-	-	-
Income Tax Payable	-	-	-	-
Equity
Common Stock Equity	$216,204,000	$337,186,000	$437,284,000	$433,803,000
Total Equity Gross Minority Interest	$216,204,000	$337,186,000	$437,391,000	$434,024,000
Stockholders Equity	$216,204,000	$337,186,000	$437,284,000	$433,803,000
Gains Losses Not Affecting Retained Earnings	$196,000	$558,000	$2,194,000	$-1,353,000
Other Equity Adjustments	$196,000	$558,000	$2,194,000	$-1,353,000
Retained Earnings	$-1,191,455,000	$-1,054,395,000	$-888,556,000	$-596,365,000
Long Term Equity Investment	-	-	$0	$21,213,000
Other
Ordinary Shares Number	$69,085,980	$71,282,400	$70,765,554	$59,280,247
Share Issued	$69,085,980	$71,282,400	$70,765,554	$59,280,247
Tangible Book Value	$216,204,000	$337,186,000	$433,548,000	$430,067,000
Invested Capital	$216,204,000	$337,186,000	$437,284,000	$433,803,000
Working Capital	$216,632,000	$333,341,000	$427,351,000	$395,286,000
Capital Lease Obligations	$35,704,000	$39,577,000	$43,150,000	$45,166,000
Total Capitalization	$216,204,000	$337,186,000	$437,284,000	$433,803,000
Additional Paid In Capital	$1,407,394,000	$1,390,952,000	$1,323,576,000	$1,031,462,000
Capital Stock	$69,000	$71,000	$70,000	$59,000
Common Stock	$69,000	$71,000	$70,000	$59,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$35,704,000	$39,577,000	$43,150,000	$45,166,000
Current Accrued Expenses	$29,351,000	$45,287,000	$54,441,000	$45,400,000
Net PPE	$29,041,000	$37,227,000	$41,735,000	$50,078,000
Accumulated Depreciation	$-2,774,000	$-4,274,000	$-3,148,000	$-2,060,000
Gross PPE	$31,815,000	$41,501,000	$44,883,000	$52,138,000
Leases	$4,168,000	$4,168,000	$4,235,000	$4,891,000
Other Properties	$26,271,000	$35,910,000	$38,985,000	$44,995,000
Machinery Furniture Equipment	$1,376,000	$1,423,000	$1,490,000	$2,215,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$209,898,000	$337,183,000	$454,881,000	$394,302,000
Minority Interest	-	$0	$107,000	$221,000
Goodwill	-	$0	$3,736,000	$3,736,000
Construction In Progress	-	$0	$173,000	$37,000
Investments And Advances	-	-	$0	$21,213,000
Investmentsin Associatesat Cost	-	-	$0	$21,213,000
Investmentsin Joint Venturesat Cost	-	-	-	$21,213,000
Current Capital Lease Obligation	-	-	-	-
Pensionand Other Post Retirement Benefit Plans Current	-	-	-	-

Fetched: 2026-06-02

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-125,247,000	$-171,081,000	$-208,405,000	$-166,299,000
Operating Activities
Operating Cash Flow	$-125,247,000	$-170,860,000	$-207,822,000	$-163,751,000
Cash Flow From Continuing Operating Activities	$-125,247,000	$-170,860,000	$-207,822,000	$-163,751,000
Operating Gains Losses	$-660,000	$-92,000	$16,420,000	$16,338,000
Investing Activities
Investing Cash Flow	$131,623,000	$176,561,000	$-44,458,000	$-114,180,000
Cash Flow From Continuing Investing Activities	$131,623,000	$176,561,000	$-44,458,000	$-114,180,000
Capital Expenditure	-	$-221,000	$-583,000	$-2,548,000
Financing Activities
Repurchase Of Capital Stock	$-9,976,000	$0	$0	-
Issuance Of Capital Stock	$5,694,000	$349,000	$237,303,000	$261,043,000
Financing Cash Flow	$-4,282,000	$108,000	$237,303,000	$261,043,000
Cash Flow From Continuing Financing Activities	$-4,282,000	$108,000	$237,303,000	$261,043,000
Net Common Stock Issuance	$-4,282,000	$349,000	$237,303,000	$261,043,000
Common Stock Issuance	$5,694,000	$349,000	$237,303,000	$261,043,000
Net Other Financing Charges	-	$-241,000	-	-
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Income Tax Paid Supplemental Data	$85,000	$359,000	$140,000	$12,000
End Cash Position	$38,622,000	$36,528,000	$30,719,000	$45,696,000
Beginning Cash Position	$36,528,000	$30,719,000	$45,696,000	$62,584,000
Changes In Cash	$2,094,000	$5,809,000	$-14,977,000	$-16,888,000
Common Stock Payments	$-9,976,000	$0	$0	-
Net Investment Purchase And Sale	$130,925,000	$176,717,000	$-43,875,000	$-111,632,000
Sale Of Investment	$270,413,000	$304,679,000	$505,307,000	$421,529,000
Purchase Of Investment	$-139,488,000	$-127,962,000	$-549,182,000	$-533,161,000
Net PPE Purchase And Sale	$698,000	$-156,000	$-583,000	$-2,548,000
Sale Of PPE	$698,000	$65,000	$0	$0
Purchase Of PPE	$0	$-221,000	$-583,000	$-2,548,000
Change In Working Capital	$-9,122,000	$-16,540,000	$5,864,000	$13,252,000
Change In Other Working Capital	$201,000	$264,000	$623,000	$4,330,000
Change In Payables And Accrued Expense	$-17,316,000	$-18,022,000	$10,919,000	$15,527,000
Change In Payable	$-17,316,000	$-18,022,000	$10,919,000	$15,527,000
Change In Account Payable	$-17,316,000	$-18,022,000	$10,919,000	$15,527,000
Change In Prepaid Assets	$2,993,000	$6,218,000	$-5,678,000	$-6,605,000
Change In Receivables	$5,000,000	$-5,000,000	$0	$0
Changes In Account Receivables	$5,000,000	$-5,000,000	$0	$0
Stock Based Compensation	$20,722,000	$67,269,000	$54,822,000	$46,840,000
Unrealized Gain Loss On Investment Securities	$-1,239,000	$-5,228,000	$0	$0
Asset Impairment Charge	$4,136,000	$3,736,000	$4,953,000	$0
Amortization Of Securities	$-2,763,000	$-8,002,000	$-13,157,000	$-3,725,000
Deferred Tax	$0	$0	$-853,000	$-769,000
Deferred Income Tax	$0	$0	$-853,000	$-769,000
Depreciation Amortization Depletion	$739,000	$1,289,000	$1,389,000	$1,426,000
Depreciation And Amortization	$739,000	$1,289,000	$1,389,000	$1,426,000
Earnings Losses From Equity Investments	$0	$0	$16,014,000	$16,282,000
Gain Loss On Sale Of PPE	$-660,000	$-13,000	$406,000	$56,000
Gain Loss On Sale Of Business	$0	$-79,000	$0	$0
Net Income From Continuing Operations	$-137,060,000	$-165,867,000	$-292,305,000	$-237,113,000
Other Non Cash Items	-	$-47,425,000	$15,045,000	-
Net Business Purchase And Sale	-	-	$0	$0
Purchase Of Business	-	-	$0	$0

Fetched: 2026-06-02